<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30036884</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>07</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-0232</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>94 Suppl 1</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Oncology</Title>                <ISOAbbreviation>Oncology</ISOAbbreviation>            </Journal>            <ArticleTitle>Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.</ArticleTitle>            <Pagination>                <MedlinePgn>19-28</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000489065</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Predictive factors of response to eribulin are lacking. We aimed to investigate the activity and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed 71 eribulin-treated MBC patients. Best response rate, PFS, and adverse events (AEs) were evaluated. The impact of different clinical-pathological factors on PFS was evaluated using the Cox proportional hazards model. Predictive factors of response were identified by discriminant function analysis (DFA).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Median PFS was 3.75 months (95% CI, 2.39-4.48); 12 patients (16.90%) achieved partial response (PR), 27 (38.03%) stable disease. The most common AEs were fatigue (25.83%), neutropenia (16.56%), and peripheral neuropathy (13.91%). A worse performance status (p = 0.025) and a higher number of metastatic organ sites (p = 0.011) were associated with a worse PFS under eribulin. Overall, in the DFA-predictive model, neutrophil-to-lymphocyte ratio at baseline, estrogen receptor, Ki67, histology, and age were predictive of PR with 100% accuracy.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Activity and safety profiles of eribulin were consistent with literature data. Performance status and number of metastatic sites were predictive factors of PFS. DFA could be a promising tool to discriminate responses to eribulin among MBC patients.</AbstractText>                <CopyrightInformation>© 2018 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>De Sanctis</LastName>                    <ForeName>Rita</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Molecular and Cellular Networks Lab, Department of Anatomy, Histology, Forensic Medicine and Orthopaedics, &quot;Sapienza&quot; University, Rome, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Agostinetto</LastName>                    <ForeName>Elisa</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Masci</LastName>                    <ForeName>Giovanna</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferraro</LastName>                    <ForeName>Emanuela</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Losurdo</LastName>                    <ForeName>Agnese</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Viganò</LastName>                    <ForeName>Alessandro</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Molecular and Cellular Networks Lab, Department of Anatomy, Histology, Forensic Medicine and Orthopaedics, &quot;Sapienza&quot; University, Rome, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Antunovic</LastName>                    <ForeName>Lidija</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zuradelli</LastName>                    <ForeName>Monica</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Torrisi</LastName>                    <ForeName>Rosalba Maria Concetta</ForeName>                    <Initials>RMC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Santoro</LastName>                    <ForeName>Armando</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Oncology</MedlineTA>            <NlmUniqueID>0135054</NlmUniqueID>            <ISSNLinking>0030-2414</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>LR24G6354G</RegistryNumber>                <NameOfSubstance UI="C490954">eribulin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Drugs Context. 2017 Nov 08;6:212506</RefSource>                <PMID Version="1">29167692</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2004 Aug 15;64(16):5760-6</RefSource>                <PMID Version="1">15313917</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2014 Mar 20;5(5):320-7</RefSource>                <PMID Version="1">24723974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2014 Feb;10(3):363-76</RefSource>                <PMID Version="1">24367990</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2008 Jul;7(7):2003-11</RefSource>                <PMID Version="1">18645010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Mar 12;377(9769):914-23</RefSource>                <PMID Version="1">21376385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biometrics. 1997 Dec;53(4):1284-92</RefSource>                <PMID Version="1">9423250</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Transl Oncol. 2018 Apr;20(4):476-483</RefSource>                <PMID Version="1">28785911</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2015 Oct 08;15:659</RefSource>                <PMID Version="1">26449988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Res Int. 2018 Apr 23;2018:2786163</RefSource>                <PMID Version="1">29850497</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2005 Jul;4(7):1086-95</RefSource>                <PMID Version="1">16020666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2017 Feb 6;12(2):e0170634</RefSource>                <PMID Version="1">28166544</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64</RefSource>                <PMID Version="1">21960707</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Nov 20;28(33):4877-83</RefSource>                <PMID Version="1">20921468</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Medicine (Baltimore). 2017 Nov;96(45):e8101</RefSource>                <PMID Version="1">29137007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2014 Mar 18;110(6):1497-505</RefSource>                <PMID Version="1">24569463</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource>                <PMID Version="1">19097774</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Springerplus. 2016 Jan 21;5:59</RefSource>                <PMID Version="1">26835238</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Differ. 2014 Jan;21(1):15-25</RefSource>                <PMID Version="1">23787994</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2014 Feb;10(2):233-9</RefSource>                <PMID Version="1">24490609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Jun 20;27(18):2954-61</RefSource>                <PMID Version="1">19349550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Pharmacother. 2011 Dec;12(18):2883-90</RefSource>                <PMID Version="1">22087618</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2014 Oct;105(10):1334-42</RefSource>                <PMID Version="1">25060424</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2016 May 19;16:320</RefSource>                <PMID Version="1">27198767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2017 Jan 5;19(1):2</RefSource>                <PMID Version="1">28057046</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Discriminant functional analysis</Keyword>            <Keyword MajorTopicYN="N">Eribulin</Keyword>            <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">Progression-free survival</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30036884</ArticleId>            <ArticleId IdType="pii">000489065</ArticleId>            <ArticleId IdType="doi">10.1159/000489065</ArticleId>            <ArticleId IdType="pmc">PMC6193748</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>